Quarterly Statement Of Cash Flows

Modalis Therapeutics Corporation - Filing #7612938

Concept As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
As at
2019-12-31
Quarterly statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-791,714,000 JPY
-745,417,000 JPY
-467,548,000 JPY
-439,549,000 JPY
Depreciation
77,870,000 JPY
57,588,000 JPY
Interest and dividend income
-57,000 JPY
-52,000 JPY
Interest expenses
1,090,000 JPY
JPY
Foreign exchange losses (gains)
-11,729,000 JPY
3,393,000 JPY
Decrease (increase) in trade receivables
JPY
6,600,000 JPY
Other, net
-112,179,000 JPY
477,000 JPY
Subtotal
-1,232,400,000 JPY
-375,756,000 JPY
Interest and dividends received
57,000 JPY
52,000 JPY
Income taxes paid
-1,210,000 JPY
-950,000 JPY
Net cash provided by (used in) operating activities
-747,466,000 JPY
-376,575,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-107,111,000 JPY
-15,148,000 JPY
Other, net
332,000 JPY
427,000 JPY
Net cash provided by (used in) investing activities
171,563,000 JPY
-830,310,000 JPY
Cash flows from financing activities
Proceeds from issuance of shares
JPY
2,749,145,000 JPY
Purchase of treasury shares
-97,000 JPY
JPY
Other, net
JPY
-169,000 JPY
Net cash provided by (used in) financing activities
72,633,000 JPY
2,777,992,000 JPY
Effect of exchange rate change on cash and cash equivalents
17,987,000 JPY
-6,865,000 JPY
Net increase (decrease) in cash and cash equivalents
-485,282,000 JPY
1,564,240,000 JPY
Cash and cash equivalents
4,936,193,000 JPY
5,421,476,000 JPY
3,857,235,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.